uPAR: a beacon of malignancy?

uPAR: a beacon of malignancy?

Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2008-09, Vol.14 (18), p.5643-5645
Hauptverfasser: Drapkin, Ronny, Clauss, Adam, Skates, Steven
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5645
container_issue 18
container_start_page 5643
container_title Clinical cancer research
container_volume 14
creator Drapkin, Ronny
Clauss, Adam
Skates, Steven
description Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care.
doi_str_mv 10.1158/1078-0432.CCR-08-1557
format Article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587046</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_25870463</originalsourceid><addsrcrecordid>eNqljM0KgkAYAPdQpP08guALbH2rq7t2KEKKjiHdl09TM3RXNAPfvksEnTsNzMAQ4jBYMxbIDQMhKXDfW8dxQkFSFgRiQuyvt8i87x8AjDPgM2IxKSIOYWQTZ7gckq2LbppjZrRrCrfBuio16mzcL8m0wLrPVx8uyO50vMZn2g5pk9-yXD87rFXbVQ12ozJYqd-iq7sqzUt5gRTAQ__vwRvH6Ulo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>uPAR: a beacon of malignancy?</title><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Drapkin, Ronny ; Clauss, Adam ; Skates, Steven</creator><creatorcontrib>Drapkin, Ronny ; Clauss, Adam ; Skates, Steven</creatorcontrib><description>Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care.</description><identifier>ISSN: 1078-0432</identifier><identifier>DOI: 10.1158/1078-0432.CCR-08-1557</identifier><identifier>PMID: 18794069</identifier><language>eng</language><ispartof>Clinical cancer research, 2008-09, Vol.14 (18), p.5643-5645</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Drapkin, Ronny</creatorcontrib><creatorcontrib>Clauss, Adam</creatorcontrib><creatorcontrib>Skates, Steven</creatorcontrib><title>uPAR: a beacon of malignancy?</title><title>Clinical cancer research</title><description>Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care.</description><issn>1078-0432</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqljM0KgkAYAPdQpP08guALbH2rq7t2KEKKjiHdl09TM3RXNAPfvksEnTsNzMAQ4jBYMxbIDQMhKXDfW8dxQkFSFgRiQuyvt8i87x8AjDPgM2IxKSIOYWQTZ7gckq2LbppjZrRrCrfBuio16mzcL8m0wLrPVx8uyO50vMZn2g5pk9-yXD87rFXbVQ12ozJYqd-iq7sqzUt5gRTAQ__vwRvH6Ulo</recordid><startdate>20080915</startdate><enddate>20080915</enddate><creator>Drapkin, Ronny</creator><creator>Clauss, Adam</creator><creator>Skates, Steven</creator><scope>5PM</scope></search><sort><creationdate>20080915</creationdate><title>uPAR: a beacon of malignancy?</title><author>Drapkin, Ronny ; Clauss, Adam ; Skates, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_25870463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drapkin, Ronny</creatorcontrib><creatorcontrib>Clauss, Adam</creatorcontrib><creatorcontrib>Skates, Steven</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drapkin, Ronny</au><au>Clauss, Adam</au><au>Skates, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>uPAR: a beacon of malignancy?</atitle><jtitle>Clinical cancer research</jtitle><date>2008-09-15</date><risdate>2008</risdate><volume>14</volume><issue>18</issue><spage>5643</spage><epage>5645</epage><pages>5643-5645</pages><issn>1078-0432</issn><abstract>Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Soluble forms of urokinase plasminogen activator receptor (uPAR) represent a promising new tool in the development of a discriminatory biomarker panel that can influence patient care.</abstract><pmid>18794069</pmid><doi>10.1158/1078-0432.CCR-08-1557</doi></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2008-09, Vol.14 (18), p.5643-5645
issn 1078-0432
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2587046
source American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title uPAR: a beacon of malignancy?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A28%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=uPAR:%20a%20beacon%20of%20malignancy?&rft.jtitle=Clinical%20cancer%20research&rft.au=Drapkin,%20Ronny&rft.date=2008-09-15&rft.volume=14&rft.issue=18&rft.spage=5643&rft.epage=5645&rft.pages=5643-5645&rft.issn=1078-0432&rft_id=info:doi/10.1158/1078-0432.CCR-08-1557&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_2587046%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18794069&rfr_iscdi=true